Impact of a pharmacy-based glucose management program on glycemic control in an inpatient general medicine population.

Hosp Pract (1995)

Clinical Pharmacy Specialist, Internal Medicine, Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD.

Published: February 2014

AI Article Synopsis

  • A pharmacy-based glucose management program was evaluated in an inpatient general medicine setting to see if it could improve glycemic control.
  • A retrospective chart review of 151 patients who had blood glucose levels outside the ideal range revealed that the pharmacy program did not significantly decrease the number of days patients spent outside the target range overall.
  • However, patients with admission blood glucose levels below 200 mg/dL saw a notable improvement, while those with higher admission levels faced more complexities related to their health and social situations, leading to no overall benefit from the program.

Article Abstract

Objective: A pharmacy-based glucose management program was evaluated to determine whether improved glycemic control could be achieved in an inpatient general medicine patient population.

Methods: A retrospective chart review of 151 patients with blood glucose (BG) values outside the range of 70 to 180 mg/dL within a 24-hour period was conducted. Observations for the baseline group with no pharmacy program in place were collected from admissions during July 2010 and for the intervention group in October 2010. The primary goal of the study was to determine if the pharmacy program improved patient days within the BG range of 70 to 250 mg/dL. The odds of poor glycemic control for patients in the intervention versus baseline groups were assessed by multivariate generalized estimating equations. These methods were also used to assess patient characteristics associated with poor glycemic control.

Results: No evidence was observed that the pharmacy program decreased the number of days spent out of the targeted blood glucose range (70-250 mg/dL; odds ratio, 1.08; 95% CI, 0.88-1.24). However, the subgroup of patients whose admission BG was < 200 mg/dL (49% of the intervention group) experienced a significant reduction in days spent out of the BG range (70-250 mg/dL; odds ratio, 0.42; 95% CI, 0.22-0.82). No improvement in glycemic control was observed in patients with an admission BG ≥ 200 mg/dL; these patients had more disease- and social-related factors associated with poor glycemic control.

Conclusion: The primary finding of this analysis was that there was no global benefit of the pharmacy-based glucose management program for improving BG values compared with usual care. Patients whose admission glucose was < 200 mg/dL experienced improvement in glycemic control in the pharmacy-based program. Maintaining the BG level of the remaining patients was generally more complicated from a disease-state and social perspective and patients experienced no improvement. These patients may require a more intense, multidisciplinary approach that is better matched to the constellation of factors responsible for their condition.

Download full-text PDF

Source
http://dx.doi.org/10.3810/hp.2014.02.1097DOI Listing

Publication Analysis

Top Keywords

glycemic control
20
pharmacy-based glucose
12
glucose management
12
management program
12
pharmacy program
12
mg/dl odds
12
poor glycemic
12
patients admission
12
200 mg/dl
12
patients
9

Similar Publications

The coexistence of type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) represents a significant global health challenge, contributing to substantial morbidity, mortality, and economic burden. T2DM is the leading cause of CKD, and CKD exacerbates diabetes-related complications, creating a bidirectional relationship driven by oxidative stress, inflammation, and endothelial dysfunction. Diabetic kidney disease (DKD), affecting some individuals with T2DM, accelerates progression to end-stage renal disease (ESRD) and increases cardiovascular mortality.

View Article and Find Full Text PDF

Introduction Congenital malformations are a major cause of perinatal morbidity and mortality in developing countries and are assuming greater importance than ever before. They affect a variety of organ systems and various etiologies have been identified in literature including Toxoplasmosis, Other (syphilis, varicella-zoster, parvovirus B19), Rubella, Cytomegalovirus, Herpes Simplex (TORCH) infections, exposure to pollutants, consumption of tobacco and alcohol, and advanced maternal age. In developing countries, diagnosis is frequently delayed which leads to poorer outcomes.

View Article and Find Full Text PDF

Apolipoprotein A-IV and its derived peptide, T55-121, improve glycemic control and increase energy expenditure.

Life Metab

August 2024

National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.

It is crucial to understand the glucose control within our bodies. Bariatric/metabolic surgeries, including laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass (RYGB), provide an avenue for exploring the potential key factors involved in maintaining glucose homeostasis since these surgeries have shown promising results in improving glycemic control among patients with severe type 2 diabetes (T2D). For the first time, a markedly altered population of serum proteins in patients after LSG was discovered and analyzed through proteomics.

View Article and Find Full Text PDF

Emphysematous pyelonephritis (EPN) is a rare but severe necrotizing infection often associated with diabetes, ureteral obstruction, and gas production in the renal parenchyma and perinephric area. This report describes a 54-year-old man with type 2 diabetes who presented with right lumbar pain and was diagnosed with EPN complicated by right ureteral calculi and perinephric gas accumulation. Despite initial improvement with fluid resuscitation, antibiotics, and drainage, inadequate blood glucose control led to a worsening of the infection, eventually involving the psoas major muscle and iliac vessels.

View Article and Find Full Text PDF

The connection between COVID-19 and DM unveils a multifaceted interplay that significantly impacts disease severity and management strategies. Initial studies reveal that people with DM had higher severity rates of COVID-19 due to the infection by SARS-CoV-2. The virus solely induces hyperglycemia and, at the same time, profoundly influences the immune and inflammatory reactions, increasing the rate of severe complications and death among diabetes patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!